Description

Corcept Therapeutics: How Big Is The Relacorilant Oncology Breakthrough And Could It Transform Treatment In Ovarian Cancer?

Corcept Therapeutics recently announced its financial results for FY2025 and provided a corporate update that sheds light on both the achievements and challenges faced by the company. Corcept reported annual revenue of $761 million, an increase from the previous year’s $675 million, and anticipates continued growth with a revenue projection of $900 million to $1 billion for 2026. Net income for 2025 was $99.7 million, a decrease from $141.2 million in 2024. Cash and investments stood at $532 million, with a significant portion allocated to a $245 million stock repurchase program. Among the key issues highlighted was the unfavorable ruling by the Federal Circuit Court of Appeals regarding the company’s lawsuit against Teva Pharmaceuticals over generic marketing of Korlym, affecting Corcept’s patent protection strategy. Corcept plans to appeal this decision. Additionally, the FDA’s unexpected rejection of relacorilant for treating Cushing’s syndrome surprised the company.